CA-SOLIDIGM
26.4.2022 18:02:05 CEST | Business Wire | Press release
Today Solidigm is expanding its performance-optimized D7 Product Series with new solid-state storage drives (SSDs) — the D7-P5520 and the D7-P5620 — for data center and enterprise use. These drives are optimized for real-world compute and storage server workloads and are available in an extended range of form factors and capacities. They offer accelerated performance and reduced total cost of ownership (TCO) by enabling a smaller storage footprint and lower power consumption.
The D7-P5520 (designed for read-intensive and light mixed workloads), and the D7-P5620 (designed for mixed workloads), are the first family of products being introduced by Solidigm, which launched as a standalone company in December 2021.
The D7 Series comprises the industry’s most advanced PCIe 4.0 SSD family of products given their capacity offerings, breadth of form factors and optimized performance capabilities. These SSDs are optimized for real-world workloads and reflect insights gained from deep technical engagements with leading cloud service providers, OEMs, and storage innovators. Designed and tested with zero tolerance for data errors, consistently durable IOPS and QoS, and with near-zero lifetime performance degradation, they can be deployed with the utmost confidence.
“Our deep technical engagements spanning all industry segments give us unique customer insights to optimize our products,” said David Dixon, SVP and General Manager, Data Center, Solidigm. “The D7-P5520 and the D7-P5620 are the culmination of these insights and of multiple 3D NAND and PCIe 4.0 generations, which enable us to deliver a best-in-class offering and a new paradigm in solid-state storage.”
ByteDance partnered with Solidigm early in product development and qualified the D7-P5520 with outstanding results before live deployment in March 2022. The drives are delivering a breadth of capacity and performance improvements over prior generations, which has allowed them to boost performance by 33% with dramatic TCO improvement for database and cloud software-defined storage. The D7-P5520 will also be used in ByteDance’s public cloud services platform Volcano Engine.
Key Benefits:
-
Accelerated performance
across a range of workloads:
- D7-P5520 : up to 42% higher 4K Random Reads, 17% higher 4K Random Writes, with up to 43% better latency generation to generation. It also delivers up to 40% better read responsiveness in the presence of write pressure as compared to the competition, a key consideration for real-world workloads.
- D7-P5620: up to 56% 4K higher Random Reads, and up to 53% higher Random Writes, with up to 29% better latency generation to generation.
- Total cost of ownership (TCO) can be reduced through the combination of higher performance and expanded capacities. For example, OEMs designing for a 10M IOPS 2U server can reduce the storage footprint up to 27% while reducing power consumption up to 20% generation over generation.
- The D7 Series can be used in a wide array of storage configurations , including 1U and 2U tiered and monolithic configurations in compute and storage servers. The drives are available with extended capacity ranges and in multiple form factors, including E1.L and multiple E1.S offerings.
- Qualifications can be streamlined since Solidigm’s D7-P5520 and D7-P5620 family of products share common NAND, firmware, and controllers across SKUs.
- Quality and reliability are designed into these drives. For example, extra firmware checks are added to validate that data was saved accurately in the event of power loss. Additionally, the drives have been rigorously tested beyond industry specifications and common industry practices.
Visit solidigm.com for more information on the D7-P5620, the D7-P5520, and the full D7 Series, tuned for real-world mixed and performance-sensitive workloads. You can also learn more during a live webinar on June 15, 2022, 9 a.m. PT. Information and registration .
ABOUT SOLIDIGM
Solidigm is a leading global provider of innovative NAND flash memory solutions. Solidigm technology unlocks data’s unlimited potential for customers, enabling them to fuel human advancement. Our origins reflect Intel’s longstanding innovation in memory products and SK hynix’s international leadership and scale in the semiconductor industry. Solidigm became a standalone U.S. subsidiary under SK hynix in December 2021. Headquartered in San Jose, CA, Solidigm is powered by the inventiveness of close to 2,000 employees in 20 locations around the world. For more information, please visit solidigm.com and follow us on Twitter at @Solidigm and on LinkedIn .
All products, computer systems, dates, and figures specified are preliminary based on current expectations, and are subject to change without notice.
Tests document performance of components on a particular test, in specific systems. Differences in hardware, software, or configuration will affect actual performance. Consult other sources of information to evaluate performance as you consider your purchase.
Performance results are based on testing as of dates shown in the configurations and may not reflect all publicly available updates. See configuration disclosure for details. No product or component can be absolutely secure.
Solidigm optimizations, for Solidigm compilers or other products, may not optimize to the same degree for non-Solidigm products.
Solidigm technologies may require enabled hardware, software, or service activation.
Your costs and results may vary.
© Solidigm. “Solidigm” is a trademark of SK hynix NAND Product Solutions Corp. “Intel” is a registered trademark of Intel Corporation. Other names and brands may be claimed as the property of others.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220426005470/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
European Commission Approves DAYBU® (trofinetide) as the First and Only Treatment for Neurobehavioral Symptoms of Rett Syndrome in the European Union24.8.2026 09:01:00 CEST | Press release
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the European Commission (EC) has granted marketing authorization for DAYBU (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older, making it the first and only treatment approved for Rett syndrome in the European Union (EU). “The approval of DAYBU marks a significant milestone for the Rett syndrome community in the EU and advances our mission to bring this innovative treatment to patients and families who have long faced a profound unmet medical need,” said Catherine Owen Adams, Acadia’s Chief Executive Officer. “For people living with Rett syndrome, a devastating rare neurodevelopmental disorder, there have been no approved treatment options in the EU. We are proud to make DAYBU available and look forward to supporting patients, caregivers, and healthcare providers gain access to treatment." The DAYBU marketing authorization in the EU is prim
ORZEYFUL (oveporexton) Approved in Japan as the First and Only Medicine to Treat the Underlying Cause of Narcolepsy Type 124.8.2026 08:36:00 CEST | Press release
Discovered by Takeda in Japan, ORZEYFUL has the Potential to Redefine Care Beyond Individual Symptom Management for Adults Living with Narcolepsy Type 1 (NT1) Landmark Phase 3 Studies Demonstrated Significant and Meaningful Improvements Across the Full Range of NT1 Symptoms Evaluated in Clinical Trials Compared to Placebo Milestone Marks Third Major Regulatory Approval Secured for ORZEYFUL Around the World Takeda (TOKYO:4502/NYSE:TAK) announced that the Japanese Ministry of Health, Labour and Welfare (MHLW) approved the use of ORZEYFUL (oveporexton) for the treatment of narcolepsy type 1 (NT1, narcolepsy with cataplexy) in adults. ORZEYFUL is a first-in-class oral orexin receptor 2 (OX2R) agonist and the only medicine indicated in Japan to treat the disease holistically rather than individual symptoms. The discovery of this new class of medicine originated in Takeda's laboratories in Japan. Takeda is proceeding with launch preparations and expects to make ORZEYFUL available as quickly
Fasset Hits $1B Valuation as SBI Group Leads $68M Series C to Scale AI-Powered Stablecoin Neobanking24.8.2026 08:03:00 CEST | Press release
Round led by SBI Group follows $51 million Series B raise in May 2026, marking ascent as one of the fastest-growing neobanking platforms. Capital will expand Own Network and deepen AI across stablecoin settlement, tokenization, and corridor banking. Fasset now processes more than $40 billion in annualized transaction volume, serving 3 million+ wallets and more than 1,000 enterprises across 125 countries. Fasset, the AI-powered stablecoin neobanking platform, today announced it has raised $68 million in Series C funding at a $1 billion valuation. The financing was led by SBI Group and follows Fasset’s $51 million Series B earlier this year, which brought Speedinvest onto the cap table alongside a group of strategic investors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260823503947/en/ Mohammad Raafi Hossain, Co-Founder and CEO, Fasset The new capital will support the expansion of Own Network, Fasset’s regulated financial
Zanders Expands DACH Region with New Office in Vienna, Austria24.8.2026 07:11:00 CEST | Press release
Zanders, the global treasury, risk, and technology consultancy, today announced a significant expansion of its DACH region with the opening of a new office in Vienna. The move builds on Zanders' continued growth across Germany, Austria, and Switzerland, and marks another step in the firm's strategy of deepening its presence in the markets where client demand for specialized treasury, risk, and corporate finance advisory is growing fastest. DACH has been one of Zanders' priority regions for several years, with the firm steadily expanding its team and client base across Germany and Switzerland. Austria represents a natural next step in that growth: in conversations with clients in the market, Zanders has seen growing interest in treasury transformation and financing support, as companies work through interest rate volatility, refinancing needs, and a broader shift toward more digitized, centralized treasury operations. The new Vienna office allows Zanders to be closer to clients' operati
Novotech Strengthens Presence in Japan with Opening of Tokyo Office24.8.2026 01:01:00 CEST | Press release
Novotech, a leading global biotech CRO and full-service clinical research organization, has strengthened its established presence in Japan with the opening of a new office in Tokyo. The investment builds on Novotech’s existing operations and clinical trial activity in Japan and further enhances its ability to support Japanese biopharma companies as they advance programs regionally and across key international markets. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260823592174/en/ Takeshi Mori, Novotech Country Head, Japan The Tokyo office will serve as a strategic hub for Novotech’s growing operations in Japan, providing enhanced local expertise and strengthening collaboration with clients, partners, research institutions, and innovation ecosystems across the region. Novotech is currently supporting ongoing studies in Japan and provides sponsors with integrated support across early-phase clinical development in Australia, F
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
